Novartis Gene Therapies, Inc. et al. vs. Genzyme Corporation et al.
Explore the PTAB proceeding IPR2023-00608 filed by Novartis Gene Therapies, Inc. et al. on 2023-02-22. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2023-00608
Filing Date
2023-02-22
Accorded Filing Date
2023-02-22
Institution Decision Date
2023-08-30
Last Modified Date
—
Proceeding Type
IPR
Termination Date
2023-08-30
Trial Status
Institution Denied
Parties & Counsel
Petitioner
Novartis Gene Therapies, Inc. et al.
Represented By
Livingstone, Johnet alPatent Owner / Respondent
Genzyme Corporation et al.
Represented By
Antons, Amandaet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
1 Total
Proceeding Status
Institution Denied
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 36844 | Joseph Kirk Jr | +1 908-981-6911 |
| 39150 | John Conway | +1 908-981-6688 |
| 40564 | Anne Collins | +1 978-341-0036 |
| 44045 | Sandra Brockman-Lee | +1 857-523-9199 |
| 45736 | Pamela Torpey | +1 508--27-1-0683 |
| 45979 | Milan Vinnola | +1 619-238-0062 |
| 47150 | Nicole Parsons | +1 617-685-5697 |
| 52610 | Kelly Bender | +1 248-593-0581 |
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 9,051,542 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2016008369 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2017024766 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 57,599,704 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 63,922,204 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,704,721 B2 | US Continuation / Sibling | View Official Patent → |
Sarepta Therapeutics, Inc. et al. v. Genzyme Corporation et al.
Sarepta Therapeutics, Inc. et al. v. Genzyme Corporation et al.
Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation et al.